Applied Genetic Technologies

Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied Genetic Technologies Corp. (NASDAQ: AGTC) shares were crushed early Thursday after the firm reported interim data from its midstage trial in patients with achromatopsia.

Are Investors Overreacting to This Achromatopsia Study?

–Encouraging preliminary signs of biologic activity and a favorable safety profile are outcomes that are  clinically relevant to patients

AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia

Applied Genetic Technologies Should Be On Your Radar After Latest Rare Disease Eye Data

Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.

Applied Genetic Stock Up on Favorable Eye Therapy Study Data

Investors need to pay close attention to Applied Genetic Technologies (AGTC) stock based on the movements in the options market lately.

Implied Volatility Surging for Applied Genetic Technologies (AGTC) Stock Options

Applied Genetic Technologies Corp. (NASDAQ: AGTC) shares jumped by more than 50% on Thursday after the firm announced positive interim data from its midstage trial in X-linked retinitis pigmentosa (XLRP).

How This Eye Study Is Making Waves

Shares of micro-cap gene therapy company Applied Genetic Technologies Corp (NASDAQ: AGTC) were advancing to their highest level in more than a year Thursday after the company released a positive midstage readout for its gene therapy to treat an inherited eye disorder.

Applied Genetic Shares Rip Higher After Eye Disorder Gene Therapy Aces Midstage Trial

Shares of Applied Genetic Technologies Corp. AGTC, -2.58% soared 60% on heavy volume in premarket trading on Thursday after the biotechnology company reported positive results from a Phase 1/2 trial for its investigational gene therapy for retinitis pigmentosa, a disorder that causes vision loss.

Applied Genetic Technologies' stock rockets on early-stage eye therapy data

- Data suggest durable and meaningfully improvements in central visual sensitivity  - Secondary data showed encouraging improvements in Best Corrected Visual Acuity  - All patients dosed continue to demonstrate a favorable safety profile  - Company plans to initiate pivotal trial by the end of 2020  - Company to host conference call and webcast with slides today at 8:00 am ET

AGTC Reports Positive Six-Month Data from its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa

Applied Genetics Technology Corporation: Strong Science And Clinical Efficacy

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec.  02, 2019  (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Theresa Heah, M.D., Chief Medical Officer, has resigned from the company to pursue other opportunities.

AGTC Announces Departure of Chief Medical Officer, Company on Track to Announce XLRP and ACHM Data in January 2020

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q1 2020 Results - Earnings Call Transcript

- Data support safety and potential clinical utility of AGTC’s ocular gene therapy candidates regardless of patients’ AAV antibody status-

AGTC Presents Data Demonstrating Efficiency of its AAV Vectors for Ocular Gene Therapy Even in the Presence of Anti-AAV Antibodies

Otonomy

Initial focus on GJB2, the most common cause of genetic hearing loss in newborns Initial focus on GJB2, the most common cause of genetic hearing loss in newborns

AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

Biotechnology company Applied Genetic Technologies Corp (NASDAQ: AGTC) presented interim six-month data Thursday for the Phase 1/2 XLRP program in X-linked retinitis pigmentosa, turning BMO Capital Markets bullish on the stock.

Applied Genetic Notches Sell-Side Upgrade After Releasing Interim Study Data

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2019 Results - Earnings Call Transcript

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -13.73% and -42.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Applied Genetic Technologies (AGTC) Reports Q4 Loss, Lags Revenue Estimates

Company announces promising topline six-month dose escalation data from its ongoing Phase 1/2 clinical trials for X-linked retinitis pigmentosa (XLRP)

AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2019

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept.  25, 2019  (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in the following conferences:

AGTC to Present at Upcoming Conferences

Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Applied Genetic Technologies (AGTC) to Report a Decline in Earnings: What to Look Out for

Anika Therapeutics

Axovant Gene Therapies Ltd

Mallinckrodt PLC

Mallinckrodt (MNK) will spin-off its Specialty Generics business to its shareholders.

Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down

Applied Genetic Technologies Corporation (AGTC) CEO SueWasher on Q3 2019 Results - Earnings Call Transcript

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of 216.67% and 4163.60%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Applied Genetic Technologies (AGTC) Q3 Earnings and Revenues Surpass Estimates

Applied Genetic Technologies (AGTC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for Applied Genetic Technologies Stock (AGTC)